Antibiotic resistance is one of the fastest growing threats to modern civilization, with an exponentially increasing number of multi-drug resistant (MDR) infections costing millions of dollars in medical fees and hundreds of lives every year. One method of antibiotic resistance elucidated in multiple gramnegative species such as Escherichia coli (E. coli) is the high functional tolerance of bacterial efflux pumps, which extrude a wide range of native metabolites and non-native toxins out of the bacterial cell membrane. At this time there is no method for inhibiting a wide range of E. coli efflux pumps, although recent research has indicated that the non-specific AcrAB-TolC efflux system is an attractive target for inhibition. Verapamil, a calcium channel blocker (CCB) typically utilized for the treatment of heart conditions, was revealed to decrease the capabilities of a range of bacterial cells, allowing for a higher rate of drug susceptibility. There is a significant lack of Verapamil’s applications in antimicrobial studies, and no work done to elucidate the effects of contrasting enantiomers in tandem with antibiotics and E. coli. This research determined that racemic Verapamil does increase the bactericidal activity of the common antibiotic Augmentin, and indicates that the (S)-enantiomer may be of significant value to decreasing necessary concentration of antibiotics for maintaining a comparable level of E. coli mortality.